ZPDH:XETRA:XETRA-SPDR S&P U.S. Health Care Select Sector UCITS (EUR)

ETF | Others |

Last Closing

USD 42.315

Change

-0.04 (-0.08)%

Market Cap

USD 0.40B

Volume

5.06K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.80 (-1.54%)

USD 426.26B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.33 (-1.97%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.13 (-0.46%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.13 (-0.44%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.23 (-0.93%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

-0.23 (-0.49%)

USD 104.42B
8R80:XETRA Amundi Index Solutions - Amund..

-0.86 (-0.60%)

USD 104.42B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.28 (-0.54%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.39 (+0.37%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+2.70 (+0.45%)

USD 80.38B

ETFs Containing ZPDH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.00% 65% D 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.00% 64% D 65% D
Trailing 12 Months  
Capital Gain 20.01% 67% D+ 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.01% 66% D+ 67% D+
Trailing 5 Years  
Capital Gain 71.39% 83% B 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.39% 82% B 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 12.27% 76% C+ 74% C
Dividend Return 12.27% 75% C 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.86% 58% F 66% D+
Risk Adjusted Return 113.08% 98% N/A 98% N/A
Market Capitalization 0.40B 61% D- 54% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike